Two years ago, Servier launched an ambitious programme of transformation to adapt to the new reality of the pharmaceutical industry. Olivier Laureau, CEO of Servier and President of the Fondation Internationale de Recherche Servier, explains the initiative and other achievements.
What would you say have been the most significant developments in the pharmaceutical industry over the past 21 years?
Three major triggers have completely changed the business model of the pharmaceutical industry:
Precision medicine and targeted therapies focusing on the highest needs for patients suffering from severe diseases
Biologics. The development of biological drugs has opened a broad new field of therapies for the benefit of patients. It has also required the industry to adapt, recruit new experts and develop new skills.
Digital transformation, e-health and big data. More and more therapeutic solutions in development for patients go beyond the pill, taking account of their needs and expectations. This represents another broad field of expertise that is required for companies to stay in the race.
[insert_php] if ( zmember_valid_subscription() ) { echo ‘
DOWNLOAD THE ENTIRE 21st ANNIVERSARY SUPPLEMENT NOW
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
Our 21 @ 21 Anniversary Supplement is just one of the many resources a free subscription to European Pharmaceutical Review provides. If you are already a subscriber, login to download the PDF.
Not yet a subscriber? Join our growing community of thousands of industry professionals and gain access to:
Bi-monthly issues in print and/or digital format
Case studies, whitepapers, webinars and industry-leading content
Breaking news and features
Our extensive online archive of over 8,500 articles and past issues
Two years ago, Servier launched an ambitious programme of transformation to adapt to the new reality of the pharmaceutical industry. The key areas are patients’ innovation, interdisciplinary and responsibility: we put the patients’ interests first in all our activities. We have also decided to focus our research on a limited number of pathologies, in our five historical therapeutic areas, chosen according to the highest unmet medical and patient needs, involving common underlying key biological processes. We also continue to develop collaborations and partnerships all over the world, with entities ranging from the best academic research teams to biotechs or other pharmas. The objective is to identify breakthrough discoveries made by research or development teams anywhere in the world – and transform them into innovative products for patients, as rapidly as possible.
Looking ahead to the next few years, what do you think are likely to be the main opportunities and challenges affecting the industry?
The current changes in the pharmaceutical industry mentioned above are not a whim. They correspond to a huge and profound mutation in the way patients approach their health, wanting to take an active part in their treatment and quality of life. So, tomorrow’s challenges will be very similar to those faced today: targeted therapies, biological treatments and e-health.
These represent tremendous opportunities. We have recently announced the launch of a new bioproduction unit in one of our French plants and we have also created an e-health department, with a lot of autonomy to work efficiently with start- ups.
Our global partnering approach is rather original. We prefer to work in collaborative partnerships, bringing our expertise to the development of highly innovative therapeutic solutions, rather than buying out these opportunities. This approach allows us to take full advantage of the creativity and agility of young innovative companies as well as the expertise and financial strengths of larger ones.
These evolutions represent interesting opportunities for companies that dare to innovate and are capable of deeply changing their mindset. In this context, Servier has considerable advantages: the quality of the 20,700 collaborators and a multi-billion Euro turnover give us sufficient strengths to innovate and proceed on well-defined fronts, while allowing us the flexibility required in this rapidly evolving world. However, our main asset is our governance, which is based on a nonprofit foundation. This means that we can reinvest all our profits in the development of new products, for the benefit of patients. This structure is particularly adapted to long development cycles in research and development.
How is Servier preparing for these developments?
As already mentioned, Servier has launched a profound transformation, recruiting new talents and expertise and setting up internal conditions to enhance interdisciplinarity and synergies. For example, we have announced the opening of a new research centre in Paris- Saclay, where our French researchers will be gathered in a highly stimulating environment, with access to the unique ecosystem of the area.
The building will offer many opportunities to interact, as well as spaces to host start-ups and biotech companies. We have also chosen to reinforce our commitment to oncology, by progressively increasing its portion of our R&D budget from 17% in 2014 to 40% today – and 50% in the coming years. Finally, we set up internal onboarding programmes for our collaborators to develop their skills, empower them to face challenges in their own areas, and build the right mindset.
What would you say has been Servier’s outstanding achievement (or achievements) of recent years, and what impact has this had on patients and potentially the industry in general?
Major achievements should be measured with patient benefits in mind. We are very proud to have brought Lonsurf to European patients for the treatment of metastatic colorectal cancer in people who have previously failed to benefit from another therapy. This product was developed by Taiho but, thanks to an exclusive license agreement signed in June 2015, we have registered and launched the product in 39 countries and made it available to many doctors and patients. According to the doctors’ feedback, the new treatment – that we continue to develop – offers real hope for patients.
We are also developing, in partnership with Novartis, our Bcl1 and Mcl1 antagonists for the treatment of malignant haemopathies and solid tumours and – with Pfizer – one of the first allogeneic cellular therapies based on CAR-T cells. Although still in phase one, these new therapies show promising results and certainly represent hope for young patients with leukaemia.
Successful innovations in pharma are likely to increasingly rely on partnerships and collaborations between manufacturers, suppliers, academics, and a whole range of other companies and organisations. What do you look for in these relationships, and can you give an example of one that has worked particularly well for Servier?
Our signing of over 50 partnerships in the past few years demonstrates our commitment to bringing innovation to patients through collaborative research. When looking for a partner, we search for innovative projects brought by expert teams who know how to work collaboratively. We believe that complementarity and synergies are the basis for strong, longlasting collaborations – which are the key to success. As an example, I would again mention UCART19. As this is potentially a breakthrough product, we had to set up the standards for each step of its development, including the optimisation of its production.
No one has ever produced allogeneic CARs at an industrial level before, as all other CAR therapies available so far rely on the engineering of the patient’s own cells. So, for a single product, we have to simultaneously work with at least five different partners, covering multiple aspects of its development, to bring the product as quickly as possible to the patients who need it.
Servier Profile
Servier is an international pharmaceutical company governed by a non-profit foundation and headquartered in France. With a strong international presence in 148 countries and a turnover of €4.15bn in 2017, Servier employs 20,700 people worldwide. Totally independent, the group invests 25% of its turnover (excluding generic drugs) in research and development – and dedicates all profits to its development. Corporate growth is driven by the company’s constant search for innovation in five areas of excellence:
Cardiovascular diseases
Type II diabetes
Cancer
Immune-inflammatory
Neurologic and psychiatrc diseases.
The group also drives growth through its activities in high-quality generic drugs.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.